Acorda Therapeutics (ACOR) Revenue & Revenue Breakdown


OverviewOwnershipFinancialsChartTranscripts

Acorda Therapeutics Revenue Highlights


Latest Revenue (Y)

$102.42M

Latest Revenue (Q)

$20.29M

Main Segment (Y)

Product

Acorda Therapeutics Revenue by Period


Acorda Therapeutics Revenue by Year

DateRevenueChange
2023-12-31$102.42M-13.62%
2022-12-31$118.57M-8.14%
2021-12-31$129.07M-15.62%
2020-12-31$152.97M-20.50%
2019-12-31$192.41M-59.19%
2018-12-31$471.43M-19.86%
2017-12-31$588.29M13.22%
2016-12-31$519.60M5.47%
2015-12-31$492.66M22.71%
2014-12-31$401.48M19.34%
2013-12-31$336.43M10.01%
2012-12-31$305.81M4.65%
2011-12-31$292.24M53.00%
2010-12-30$191.00M249.36%
2009-12-31$54.67M14.31%
2008-12-31$47.83M21.12%
2007-12-31$39.49M44.37%
2006-12-31$27.35M431.55%
2005-12-31$5.15M973.11%
2004-12-31$479.50K-43.98%
2003-12-31$856.00K-

Acorda Therapeutics generated $102.42M in revenue during NA 2023, up -13.62% compared to the previous quarter, and up 21.73% compared to the same period a year ago.

Acorda Therapeutics Revenue by Quarter

DateRevenueChange
2024-03-31$20.29M-46.59%
2023-12-31$37.98M37.06%
2023-09-30$27.71M-6.60%
2023-06-30$29.68M33.32%
2023-03-31$22.26M-29.28%
2022-12-31$31.47M-6.08%
2022-09-30$33.51M7.92%
2022-06-30$31.05M37.80%
2022-03-31$22.53M-39.04%
2021-12-31$36.97M17.52%
2021-09-30$31.46M-1.04%
2021-06-30$31.79M10.13%
2021-03-31$28.86M-24.37%
2020-12-31$38.16M-28.12%
2020-09-30$53.09M57.93%
2020-06-30$33.62M19.64%
2020-03-31$28.10M-44.35%
2019-12-31$50.50M5.81%
2019-09-30$47.72M-4.66%
2019-06-30$50.05M13.40%
2019-03-31$44.14M-36.17%
2018-12-31$69.15M-51.58%
2018-09-30$142.81M-6.84%
2018-06-30$153.30M44.40%
2018-03-31$106.17M-43.65%
2017-12-31$188.40M33.55%
2017-09-30$141.06M1.17%
2017-06-30$139.44M16.80%
2017-03-31$119.39M-15.10%
2016-12-31$140.63M3.70%
2016-09-30$135.61M6.40%
2016-06-30$127.46M9.97%
2016-03-31$115.90M-11.46%
2015-12-31$130.90M-11.67%
2015-09-30$148.20M30.33%
2015-06-30$113.71M13.88%
2015-03-31$99.85M-15.29%
2014-12-31$117.87M11.24%
2014-09-30$105.96M9.09%
2014-06-30$97.13M20.63%
2014-03-31$80.52M-13.04%
2013-12-31$92.59M9.04%
2013-09-30$84.92M-2.45%
2013-06-30$87.05M21.13%
2013-03-31$71.86M-11.79%
2012-12-31$81.47M5.21%
2012-09-30$77.44M2.35%
2012-06-30$75.66M6.19%
2012-03-31$71.25M-1.92%
2011-12-31$72.64M-21.91%
2011-09-30$93.03M42.52%
2011-06-30$65.28M6.51%
2011-03-31$61.29M-8.25%
2010-12-30$66.80M5.00%
2010-09-30$63.62M48.53%
2010-06-30$42.84M141.36%
2010-03-31$17.75M22.90%
2009-12-31$14.44M-5.08%
2009-09-30$15.21M21.23%
2009-06-30$12.55M0.64%
2009-03-31$12.47M0.06%
2008-12-31$12.46M-0.03%
2008-09-30$12.47M9.48%
2008-06-30$11.39M-1.11%
2008-03-31$11.51M2.66%
2007-12-31$11.22M-

Acorda Therapeutics generated $20.29M in revenue during Q1 2024, up -46.59% compared to the previous quarter, and up 64.47% compared to the same period a year ago.

Acorda Therapeutics Revenue Breakdown


Acorda Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Product$102.42M$103.84M$114.19M$124.83M$180.74M
Royalty$15.11M$14.88M$13.14M$11.67M-
Ampyra$63.94M$84.56M$98.89M$163.16M-
License Revenue$99.00K----
License-$500.00K---
Inbrija--$29.63M$24.23M$15.30M
Milestone Revenue1---$15.00M-
Other Product---$1.71M$2.27M

Acorda Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (56.41%), Ampyra (35.21%), Royalty (8.32%), and License Revenue (0.05%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19
Inbrija$4.72M$8.09M$8.29M$5.59M$3.67M$10.39M$7.80M$6.44M$5.00M$9.33M$5.83M$4.71M$4.35M$6.14M$4.89M$3.01M----
Royalty$2.39M$5.40M$2.50M$3.69M$3.53M$3.65M$3.05M$3.57M$3.96M$4.08M$3.60M$3.59M$3.62M$3.48M$3.40M$2.82M$3.43M$3.09M$2.92M$2.86M
Product$17.88M$32.56M$25.18M$25.96M$18.72M$27.82M$29.96M$27.48M$18.57M$32.89M$27.85M$28.20M$25.25M$34.68M$34.69M$30.79M$24.67M$47.41M$44.80M$47.19M
License Revenue$23.00K$31.00K$34.00K$23.00K$11.00K$500.00K--------------
Ampyra$11.50M$18.70M$15.72M$16.91M$12.61M$21.11M$18.18M$14.90M$22.52M$20.03M$21.76M$20.25M$25.34M$27.34M$26.08M$20.12M$40.78M$37.65M$44.18M-
License--------------------
Other Product----------$21.00K-$1.00K$5.00K$1.51M-$194.00K$493.00K$2.26M-
Milestone--------------$15.00M-----

Acorda Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (48.98%), Ampyra (31.49%), Inbrija (12.93%), Royalty (6.54%), and License Revenue (0.06%).

Acorda Therapeutics Peer Comparison by Revenue


TickerCompanyLast Year RevenueLast Quarter Revenue
PTPIPetros Pharmaceuticals$5.82B$1.39M
PCRXPacira BioSciences$674.98M$178.02M
LFCRLifecore Biomedical$128.26M$24.70M
ACORAcorda Therapeutics$102.42M$20.29M
DERMJourney Medical$79.18M$14.86M
CPIXCumberland Pharmaceuticals$39.55M$9.85M
BFRIBiofrontera$34.01M$7.83M
UPCUniverse Pharmaceuticals$32.31M$13.84M
AGRXAgile Therapeutics$19.59M$5.58M
SNOASonoma Pharmaceuticals$12.73M$3.44M
JUPWSafety Shot$6.20M$910.01K
EVOKEvoke Pharma$5.18M$1.74M
AKANAkanda$2.16M$762.61K
LSDILucy Scientific Discovery$7.05K$9.68K
SHPHShuttle Pharmaceuticals--
PRFXPainReform--

ACOR Revenue FAQ


Acorda Therapeutics's yearly revenue for 2023 was $102.42M, representing a decrease of -13.62% compared to 2022. The company's yearly revenue for 2022 was $118.57M, representing a decrease of -8.14% compared to 2021. ACOR's yearly revenue for 2021 was $129.07M, representing a decrease of -15.62% compared to 2020.

Acorda Therapeutics's quarterly revenue for Q1 2024 was $20.29M, a -46.59% decrease from the previous quarter (Q4 2023), and a -8.85% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $37.98M, a 37.06% increase from the previous quarter (Q3 2023), and a 20.69% increase year-over-year (Q4 2022). ACOR's quarterly revenue for Q3 2023 was $27.72M, a -6.60% decrease from the previous quarter (Q2 2023), and a -17.30% decrease year-over-year (Q3 2022).

Acorda Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -20.65%, and for the last 5 years (2019-2023) was -46.77%.

Acorda Therapeutics's revenue streams in c 23 are Product, Royalty, Ampyra, and License Revenue. Product generated $102.42M in revenue, accounting 56.41% of the company's total revenue, down -1.37% year-over-year. Royalty generated $15.11M in revenue, accounting 8.32% of the company's total revenue, up 1.55% year-over-year. Ampyra generated $63.94M in revenue, accounting 35.21% of the company's total revenue, down -24.38% year-over-year. License Revenue generated $99K in revenue, accounting 0.05% of the company's total revenue

For the fiscal year ending Dec 23, the largest source of revenue of Acorda Therapeutics was Product. This segment made a revenue of $102.42M, representing 56.41% of the company's total revenue.